Zydus receives final approval from USFDA for Bortezomib for Injection

article continues after this advertisement

Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) has received final approval from the United States Food and Drug Administration (USFDA) to market Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial (USRLD: Velcade). Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma. The medication works by slowing or stopping the growth of cancer cells.

The drug will be manufactured at Zydus Hospira. Velcade has a market size of USD 1,172mn (as per IQVIA MAT Mar’22).

The group now has 331 approvals and has so far filed over 400 ANDAs since the commencement of filing process in FY 2003-04.